Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02215252 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT02215252 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 141 participants.
The verdict
NCT02215252, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy (DPN)
Interventions
- DRUG PF-05089771 150 mg
- DRUG Matched placebo for PF-05089771 150 mg and pregabalin 300 mg
- DRUG Pregabalin 300 mg
- DRUG PF-05089771 150 mg + Pregabalin 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2014-11-10 |
| Est. Completion | 2015-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02215252
The ClinicalTrials.gov registry entry for NCT02215252 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PF-05089771 150 mg is the first listed.
NCT02215252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02215252 about?
NCT02215252 is a clinical study titled "A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)". The purpose of this study is to evaluate the efficacy and safety of PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy (DPN)
What is the current status of trial NCT02215252?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2014-11-10. Estimated completion is 2015-09-28.
What interventions are being tested in trial NCT02215252?
The interventions under investigation include: PF-05089771 150 mg (DRUG), Matched placebo for PF-05089771 150 mg and pregabalin 300 mg (DRUG), Pregabalin 300 mg (DRUG), PF-05089771 150 mg + Pregabalin 300 mg (DRUG).
Who is sponsoring clinical trial NCT02215252?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.